Patent application number | Description | Published |
20100048571 | Organic Compounds - The present disclosure relates to XIAP inhibitor compound of the formula I: | 02-25-2010 |
20100076013 | Methods of Treatment - The present invention relates to methods of treating hematological malignancies, including acute myeloid leukemia (AML), comprising the use of compounds that inhibit the binding of the Smac protein to IAPs (“IAP inhibitor”). The present invention also relates to the use of IAP inhibitors for the preparation of a medicament to treat hematological malignancies, including AML. | 03-25-2010 |
20100249405 | Organic Compounds - The present invention relates to novel IAP inhibitor compounds of formula I: | 09-30-2010 |
20100316573 | Organic Compounds - A method to predict which patients will respond to a IAP inhibiting compound comprising:
| 12-16-2010 |
20110015232 | Pyrrolydine Derivatives as IAP Inhibitors - The present invention relates to novel IAP inhibitor compounds of: Formula (I). | 01-20-2011 |
20110065726 | Organic Compounds - The present invention is directed to a compound of the formula: | 03-17-2011 |
20110281875 | Inhibitors of IAP - Novel compounds that inhibit the binding of the Smac protein to Inhibitor of Apoptosis Proteins (IAPs) of the formula (I). | 11-17-2011 |
20120196793 | BIOMARKERS FOR IAP INHIBITOR COMPOUNDS - A method to predict which patients will respond to a IAP inhibiting compound comprising administering an IAP inhibitor compound to a patient/and measuring IL1B, Lymphotoxin alpha (LTa), TWEAK, LIGHT, Fas, TNF alpha or TRAIL levels. | 08-02-2012 |
20130005663 | SMAC PEPTIDOMETICS USEFUL AS IAP INHIBITORS - The present invention is directed to a compound of the formula: | 01-03-2013 |
20140004101 | SMAC PEPTIDOMETICS USEFUL AS IAP INHIBITORS | 01-02-2014 |